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RESUME 
Il a été montré que l'adhérence à un traitement antidépresseur varie entre 30 et 70%. Le but 
de cette étude était de comparer, dans un groupe de 144 patients ambulatoires avec un 
trouble de l'humeur et/ou un trouble anxieux traités avec des antidépresseurs, l'auto-
estimation de l'adhérence avec l'estimation de l'adhérence par le médecin, ainsi qu'avec 
l'alliance thérapeutique. Les scores d'adhérence estimés par les patients et par les médecins 
étaient significativement différents, les médecins sous-estimant l'adhérence dans 29% des 
cas et la surestimant dans 31 % des cas en comparaison avec l'évaluation des patients. 
L'adhérence mesurée par les taux plasmatiques des médicaments, malgré qu'elle soit plus 
élevée que prévue si on se réfère à des études publiées précédemment, était en accord 
avec les scores auto-estimés par les patients mais pas avec les scores estimés par les 
médecins. Finalement les scores d'alliance thérapeutique estimés par les patients et par les 
médecins n'étaient pas liés à l'auto-déclaration d'adhérence. 
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Adherence to antidepressant treatment has been shown to 
range from 30 to 70 %. The aim of this study was to compare the 
patient's self-report of adherence with the doctors' estimation 
of adherence and therapeutic alliance in 104 outpatients with 
mood and/or anxiety disorder treated with antidepressants. 
The adherence scores estimated by the patients and the doc-
tors were significantly different, the doctors underestimating 
adherence in 29 % of cases and overestimating it in 31 % of cases 
compared to the patients' evaluation. Adherence measured by 
drug plasma concentration, despite being higher than expected 
from previously published reports, was in Iine with the patients' 
self-reported score but not the doctors' estimation. Finally, the 
patients' and the doctors' Helping Alliance scores were not 
related to adherence self-report. 
won:ls 
patient compliance · medication adherence · antidepressive 
agents 
lntrndm:tion 
Depression is an important cause of disability in the world, with 
antidepressant drugs representing the mainstay of treatment. 
As in other chronic disorders, several studies have consistently 
shown that adherence with antidepressants is poor, ranging 
from 30 to 70% [1, 2]. Discontinuations are most frequent during 
the first month of therapy and factors leading to discontinua-
tions are multiple and poorly understood [1 ]. Many studies have 
examined the extent of adherence to treatment. However, there 
exists only few data on the doctor's perception of their patients' 
adherence, and they demonstrated that doctors were only able 
to correctly identify non-adherent patients in 2/3 of cases or 
fared no better than chance (for a review see [2 ]). The aim of this 
study is to evaluate the relation between the patients' adherence 
to antidepressant treatment, their doctors' perception and their 
therapeutic alliance. 
*Bath authors contributed equally to this study. 
200 adult outpatients treated with antidepressants for anxiety 
and/or mood disorders at the Hôpital de Cery, Prilly-Lausanne, 
Switzerland were approached for participation in this transver-
sal observational study. 104 patients were included, 96 patients 
being excluded because of language problems or because they 
did not agree to participate. Adherence was evaluated with an 
interview of the patients (by an investigator not involved in their 
follow-up) and antidepressant blood level measurement. The 
doctor conducting the interview had access to the patients' 
medical charts. Blood sampling took place immediately after 
recruiting and interviewing patients for the study, excluding 
thus additional drug intake. Patients were informed that the 
data collected during the study would not be transmitted to 
their treating physicians. The interview included a validated 
self-reported medication-taking scale [3]: "Do you ever forget to 
take your medicine?", "Are you careless at times about taking 
your medicine?", "When you feel better, do you sometimes stop 
taking your medicine?", "Sometimes ifyou feel worse when you 
take the medicine, do you stop taking it?". Affirmative answers 
scored one point and led to the calculation of a 0-4 point score, 
higher scores indicating poorer adherence [3]. In parallel, the 
treating doctors also evaluated their patient's adherence as a 
0-4 point score (0, very good compliance; 4, poor compliance). 
The interview also included questions on reasons for discontin-
uation of treatment and on the information received from their 
treating doctor on the correct time of administration and the 
possible side-effects of their treatment. The degree of satisfac-
tion with antidepressant treatment was also evaluated with a 
4-item questionnaire including global satisfaction, control of the 
symptoms and intensity of side-effects using 5- and 6-point Lik-
ert scales (psychometric scales used to specify the level of agree-
ment to a statement). The strength of the patient-therapist 
alliance, which is based on the collaboration and bond between 
therapist and patient, was measured by the patient's and thera-
pist's version of the Helping Alliance questionnaire (HAq-11), a 
widely used 19-item questionnaire with each item rated on a 
6-point Likert scale [4]. Written informed consent was obtained 
from ail patients. The study was approved by the psychiatry eth-
ics committee of the University of Lausanne, Switzerland. The 
plasma concentrations of ail the antidepressants except for 
nefadozone and doxepine were measured as previously des-
cribed [5-8]. Chi-squared test for association, Mann-Whitney 
U test, Kruskal-Wallis test and/or Spearman correlation were 
used. Ali tests were performed with STATA (11.0; StataCorp, 
USA), and p s 0.05 was considered as statistically significant. 
The present results are based on the data of 104 patients: 55 
(53%) men (43±11 years old) and 49 (47%) women (39±11 years 
old), mean weight of 74±16kg, 51 (50%) smokers. 88 patients 
(85 %) took other medication(s), among them 8 (8 %) took 2 anti-
depressants. The antidepressant treatments with their median 
daily dose are described in c Table 1. The median treatment 
duration was 12 months [n=87; interquartile range (IQR), 5-26 
months]. Clinical diagnosis was available for 102 patients and is 
described in o Table 1. 31 (30 %) of patients suffered from anxi-
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ety disorders, 38 (37%) from mood disorders and 33 (32%) from 
bath. 
The self-report of adherence yielded a score of 0 points (very 
good adherence) for 32 patients (31 %), 1 point for 38 patients 
(37%), 2 points for 23 patients (22 %) and 3 points for 11 patients 
(11 %). No patients had a self-estimated score of 4 points (poor 
adherence). The median score for ail patients was 1. The most 
frequent yes-answered questions were about carelessness ( 52 %) 
and forgetfulness ( 46 %), whereas discontinuation of treatment 
when feeling better ( 15 %) or worse (2 %) was Jess frequent. Self-
reported adherence scores were shown to be a useful method to 
identify non-adherent patients as compared to the micrapraces-
sor-based medication event monitoring system (MEMS), a sys-
tem which records the precise time of opening of the tablet 
container [9]. Patients with mood disorders reported a better 
adherence compared to patients with anxiety disorders, with 
82% of patients with mood disorder (n=38) reporting a score of 
O or 1 vs. 52 % of patients with anxiety disorder (n = 31; X2 = 7 .1; 
p=0.008). The self-reported adherence scores increased with 
the median treatment duration, except for patients with the 
Iowest adherence (9 months for 0-point score, 12 months for 
1-point, 23 months for 2-point and 5 months for 3-point; 
p=0.04). 
The adherence was estimated by the doctors for 99 patients. It 
yielded a score of 0 point for 23 patients (23 %), 1 point for 46 
patients (46%), 2 points for 20 patients (20%), 3 points for 8 
patients (8 %) and 4 points for 2 patients (2 %). The median 
adherence score estimated by the doctors was 1 point. The dis-
tribution of the adherence scores estimated by the patients and 
the doctors was significantly different (o Fig. la; p=0.009) even 
though the scores were correlated (p=0.32; p=0.0012). The 2 
scores matched for 39 patients; whereas the doctors overesti-
mated the score compared to the patients in 29 cases and under-
estimated it in 31 cases. This relatively poor estimation is in 
agreement with the few published reports on this subject (for a 
review see [2]). 
The self-estimation of the global satisfaction with the medica-
tion indicated that 9 patients (9%) were dissatisfied to very dis-
satisfied, 63 patients (61 %) were satisfied to very satisfied and 
32 patients (31 %) were neither satisfied nor dissatisfied. Con-
cerning the contrai of the symptoms, 12 patients ( 12 %) reported 
that their medication did not help at ail, 56 patients (54%) 
reported a little or moderate help and 36 patients (35 %) a large 
or enormous help. Among the 104 patients, 48 (46%) declared 
having side effects, which were estimated as being very light to 
light (30%), moderate to average (68%) and severe (2%). The 
most frequent reported side-effects were Joss oflibido (n=18), 
tiredness ( n = 14 ), gastraintestinal prablems ( n = 12 ), sudation 
and hot flushes (n=10), dry mouth (n=8), weightgain (n=7) and 
headache (n=6). None of these estimations was related to the 
self-reported adherence score (p>0.3). In addition, 31 patients 
(30%) estimated that their doctor did not inform them suffi-
ciently about the importance of the dose, frequency and time of 
administrations; whereas 60 patients (58%) estimated that they 
were not sufficiently informed about the possible side-effects. 
Bath answers were not related to the self-reported adherence 
score or the degree of satisfaction from treatment (p > 0.1 ). Dur-
ing the interview, 16 patients (15 %) declared having discontin-
ued the antidepressant, and most ofthem (8 out of 11 answers) 
did not inform their doctor. Among these 16 patients, 6 (38 %) 
had a self-reported adherence score of 3 points, vs. 5 of 88 
patients (6%) still taking their treatment (x2 =28.4, p<0.0005). 
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Fig. 1 Distribution of the adherence scores estimated by the patients 
and by the doctors for 99 patients with antidepressant treatment a. Help-
ing Alliance scores of the patients and of the doctors for 103 patients with 
antidepressant treatment b. 
The antidepressant blood concentration was measured for 101 
patients, and 7 patients (7%) had undetectable or very low 
plasma concentrations (in relation to the dose and the interval 
sin ce the Iast intake: < 10 % of the expected concentration [ 10] ), 
suggesting very poor or non-adherence. Their self-report of 
adherence was significantly different from the rest of the 
patients (median scores 3 and 1, respectively; p=0.02). 4 of 
these 7 patients (57%) had a self-reported score of3 points, vs~ 7 
of the other 94 patients (7%; x2 =16.6, p=0.001). In addition, 31 
patients (30%) were considered as possibly partially non-adher-
ent (concentration of antidepressant and/or its main metabolite 
inferior to 1 /3 of the expected traugh concentration for the dose 
[10] and/or if the patients declared having discontinued their 
treatment). Their self-report of adherence was also significantly 
different from the rest of the patients ( median scores 2 and 1, 
respectively; ps0.00005). 8 ofthese 31 patients (26%) had a self-
reported score of 3 points, vs. 3 of the other 71 patients (4%; 
x2=24.7, ps0.0005). On the other hand, the adherence scores 
estimated by the doctors were not significantly different 
between patients with undetectable or very Iow plasma concen-
trations vs. the others, or between patients with partial adher-
ence vs. the others (p~0.1). Thus, the self-reported adherence 
score is more in accordance with the information obtained with 
the blood concentration than the doctors' estimation of adher-
ence. Still, the observation of partial adherence deduced from 
Table 1 Clinical diagnosis according to ICD-10(n=102; patients might have up to 4 diagnoses) and antidepressant treatment (n = 104) of patients. 
Clinical diagnosis (ICD 10) Number Frequency 
mood disorders 71 70% 
bipolar disorders (F 31) 3 3% 
depression (F 32) 39 38% 
recurrent depression (F 33) 29 28% 
anxiety disorders 64 63% 
phobie disorders (F 40) 11 11 % 
anxiety disorders (F 41) 27 26% 
obsessive-compulsive disorders (F 42) 21 21% 
posttraumatic stress disorders (F 43) 2 2% 
somatoform disorders (F 45) 13 13% 
antidepressant treatment Median dose (range) [mg/d] Number Frequency 
selective serotonin reuptake inhibitors 
citalopram 40 (10-60) 
including citalopram and mirtazapine 
including citalopram and reboxetine 
paroxetine 20 (10-80) 
including paroxetine and sertraline 
fluoxetine 40 (20-60) 
sertraline 100 (25-200) 
including sertraline and mirtazapine 
lncluding sertraline and paroxetine 
fluvoxamine 125 (100-300) 
escitalopram 20 
other antidepressants 
venlafaxine 225 (75-750) 
including venlafaxine and mirtazapine 
mirtazapine 30 (15-60) 
including above-mentioned co-prescriptions 
nefadozone 450 (400-500) 
reboxetine 6 (4-8) 
tricyclic antidepressants 
clomipramine 115 (105-125) 
amitriptyline 25 
trimipramine 150 
doxepine 25 
blood concentrations and self-report after a median of 12-month 
treatment in only 30% of patients is a relatively Iow value com-
pared to the literature [1,2] and can be considered as very con-
servative. This overestimation of adherence might have been 
caused by a selection bias, non-adherent patients having refused 
more frequently to be included in the study than adherent 
patients. 
The Helping Alliance scores of the patients and the therapists 
are significantly correlated (o Fig. lb, p=0.34, p=0.0004). The 
median values (range) are 54 ( 43-63) for the patients and 44 
(37-50) for the therapists. Except for an association between the 
Helping Alliance therapist score and the doctors' evaluation of 
adherence (p= -0.22, p=0.03), Helping Alliance scores were nei-
ther correlated with the patients' self-reported adherence, nor 
the doctors' evaluation of adherence, nor the plasma concentra-
tions (p~0.2). Patients with a better global satisfaction with 
their medication had higher Helping Alliance scores, with a 
median value of 58 for satisfied to very satisfied patients vs. 49 
for dissatisfied patients and 50 for neither satisfied nor dissatis-
fied (p=0.02). Similar results were observed for the therapist 
scores ( 44, 40 and 46.5, respectively; p = 0.02 ). Patients who esti-
mated to be well informed about possible side-effects had higher 
Helping Alliance scores than the others (57 vs. 50.5; p=0.02), 
while a similar trend was observed for the information on dose, 
79 76% 
31 30% 
4 
1 
18 17% 
13 13% 
13 12% 
4 4% 
1% 
20 19% 
11 11 % 
1 
12 6% 
6 
2 2% 
2 1% 
4 4% 
2 2% 
1% 
1% 
1% 
frequency and time of administration (p=0.05). On the other 
hand, the therapist scores were not found to be different (p > 0.1 ). 
Thus, the Helping Alliance score does not seem to be related to 
adherence but to the satisfaction and information received. It 
should be mentioned that this study was conducted in an aca-
demic training institution, in which therapists may change as 
often as once every 6 months, and this circumstance might have 
affected the patient-therapist alliance. Because of this specific 
setting, generalization of these data to other settings might not 
be possible. On the other hand, the frequency of change of thera-
pists is unlikely to have contributed to a major extent to the 
adherence to treatment measured in the present study as a fast 
decline in adherence within the first 3 months of therapy has 
been constantly shown in several studies [1,2]. 
In conclusion, the estimations of adherence to antidepressant 
treatment by patients and doctors were significantly different, 
though slightly correlated. Neither score was related to satisfac-
tion with the medication, contrai of the symptoms or side-
effects. A simple self-reported adherence score was shown to be 
an easy and useful method to identify non-adherent patients. 
However, because patients were informed that data collected 
during the study would not be transmitted to their treating phy-
sicians, the reliability of the self-reported adherence score 
remains to be determined in the absence of such a non-disclo-
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sure assurance. The strength of the patient-therapist alliance 
seemed more closely related to the satisfaction with the medica-
tion and the information received on medication and side-
effects than to adherence, th us highlighting the need of patient 
education on compliance. Finally, adherence measured by drug 
plasma concentration, despite being higher than expected, was 
in line with the patients' self-reported score but not with the 
doctors' estimation. Because antidepressant treatment is a Iong-
term treatment and compliance a very important issue, thera-
peutic drug monitoring could be useful to estimate patient's 
compliance and/or in case of non-response [10]. 
The authors thank Ochsner A. (editorial assistance), Ponce E. 
(bibliographical help), Aubert A.C. and Koeb L. (logistical assist-
ance and sample analysis ). 
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